Company Overview and News
Investors in Biohaven Pharmaceutical Holding Company Ltd. (BHVN - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $45 Call had some of the highest implied volatility of all equity options today.
Prospectus Supplement No. 2 (to Prospectus dated April 5, 2018)
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. As usual, a new quarter and the second half of the trading year will begin with a shortened week due to the Independence Day holiday -- a "trading week interruptus," with July 4 landing on Wednesday.
TCBK FBIP TCYSF SIRI ISCA 1128 MT CUKPF FNBG GM.WS.A GM.WS.B GM.WS.C 1928 CBB.PRB NCMI TRBAB AYI SRRK GSKY TRBNW CCL CUK SHERF PSMT MLHR KNSA QCOM FCAU SJMHF GM.WSB PFE SBGI MT RCH SSNLF TM LSXMA NXPI CLPS ZGNX AYI.WI SJMHY MLCO ISCB CCL GM EVOP DIS HCOM F CSTM CMCSA SCHYF CSTM WYNMF LLY MGTX HMC 0880 CBB ITRM BHVN VC RHUHF SIFY 506186 FGEN GLXYENT BHR SNE SCHYY TRCO WYNMY
AMN Healthcare Services, Inc. (AMN - Free Report) is a provider of healthcare workforce solutions and staffing services. The Zacks Consensus Estimate for its current year earnings has been revised 3.3% downward over the last 60 days.
BHVN AMN BCML CHJHF BCBP CHA 0728 AHS AIT AMBA
Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) is a specialty pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 36.5% downward over the last 30 days.
LSXMB BGCP BATRK FWONB LSXMA CRUS BATRR BGCA DY FWONA MRC AMPH BHVN FWONK BATRB LSXMK RWT BATRA
Biohaven Pharmaceuticals (NYSE:BHVN) is a CNS-focused company with a strong pipeline with multiple drug candidates in late stage trials. The company recently announced a number of updates for its pipeline. For its lead candidate, rimegepant from the CGRP receptor antagonist platform, the company will report initial results from a long-term safety study in Q4 2018. In Q4 2018, the company will also produce top-line results from a Phase 3 rimegepant Zydis ODT trial.
BHVN CYAD GILD VSTM CYAD MEIP
Prospectus Supplement No. 1 (to Prospectus dated April 5, 2018)
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET